By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



333 Allerton Avenue

South San Francisco  California  94080  U.S.A.
Phone: 650-741-0900 Fax: n/a


By combining leading-edge cardiovascular genetics with recent advances in heart muscle biochemistry, MyoKardia seeks to usher in an era of precision medicine that will dramatically improve the treatment of cardiomyopathies and make a meaningful difference in the lives of millions of people suffering from cardiovascular diseases. Available treatments for patients suffering from these forms of heart disease have been approved for other illnesses and only treat the symptoms of their disease. MyoKardia’s approach targets the genetic mutations that are the underlying causes of cardiomyopathy, addressing the fundamental mechanisms of the disease. This genetically targeted approach has the potential to revolutionize the treatment of cardiomyopathies, and ultimately a broader spectrum of cardiovascular disease, including heart failure.

MyoKardia was launched in 2012 by experts in cardiovascular disease genetics and muscle biology, who are acknowledged as the world leaders in their fields and are harnessing biology-based innovation to create new kinds of medicines. The company is backed by funding from leading healthcare investor Third Rock Ventures.

HR Exec Reveals In-Demand Jobs at MyoKardia

Key Statistics

Email: n/a
Ownership: Private

Web Site: MyoKardia
Employees: n/a


Company News
MyoKardia Presents Additional Positive Data From Phase II PIONEER-HCM Study Of Mavacamten (Formerly MYK-461) At The Heart Failure Society Of America’s 21st Annual Scientific Meeting 9/19/2017 11:16:22 AM
MyoKardia Announces Closing Of Public Offering Of Common Stock Including Full Exercise Of Option To Purchase Additional Shares 8/14/2017 10:54:43 AM
MyoKardia Announces Pricing Of Public Offering Of Common Stock 8/9/2017 11:20:12 AM
MyoKardia Announces Proposed Public Offering Of Common Stock 8/8/2017 8:52:27 AM
MyoKardia Shares Surge on Positive Phase II Results for Heart Muscle Disease 8/7/2017 6:40:39 AM
MyoKardia Appoints David Meeker, M.D., To Board Of Directors 4/18/2017 8:11:53 AM
MyoKardia Announces Pricing Of Proposed Public Offering Of Common Stock Publication 9/28/2016 7:28:28 AM
MyoKardia Announces Proposed Public Offering Of Common Stock 9/27/2016 7:28:45 AM
MyoKardia Names Mary Cranston To Board Of Directors 4/13/2016 11:44:44 AM
MyoKardia Publishes Article In Science Demonstrating That MYK-461 Prevents And Reverses Disease In Genetic Mouse Models Of Hypertrophic Cardiomyopathy 2/5/2016 9:20:52 AM